Non-dilutive funding extends Ovid's operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25 ...

Within the family program agenda, Aardvark's Chief Medical Officer, Manasi Jaiman, M.D., will join a panel of clinicians to discuss the details of the company's ongoing Phase 3 HERO study.

Arkay Beverages, the pioneer in zero-proof spirits, is proud to announce that its entire range — including whisky, vodka, rum ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company ...

SandboxAQ releases over 5 million AI-generated protein-drug structures to accelerate drug discovery and rival lab testing.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that the ...

A sugar in sea cucumbers may block a cancer-linked enzyme without affecting blood clotting or requiring pig-based drugs.

Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, United States ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...